Merck & Co., Inc. (MRK)

Merck's stock price has experienced fluctuations in the past six months. As of early May 2026, MRK stock was down 5.85% over the past 30 days but up 41.94% over the past 12 months. The stock hit a 4-week low of $114.70 USD on April 21, 2026, and a 4-week high of $121.53 USD on March 30, 2026. Merck reported better-than-expected quarterly results on April 30, 2026, with Q1 2026 earnings per share (EPS) of -$1.28, beating analysts' estimates of -$1.47. Revenue for the quarter was $16.29 billion, surpassing expectations of $15.85 billion. The company also reaffirmed its full-year 2026 guidance for EPS between $5.04 and $5.16. Analyst ratings have generally been positive, with a consensus of "Moderate Buy" from 19 brokerages.

Demand for some of Merck's products exhibits seasonality. Sales of ENFLONSIA, an RSV monoclonal antibody, are expected to be minimal in the second quarter due to its seasonal nature and high inventory levels in the market. Shipments for this product are anticipated to increase in the second half of the year, aligning with the RSV season. The company actively engages customers and educates healthcare professionals and parents on the importance of protecting infants from RSV in advance of the season.

Merck & Co., Inc. is a global healthcare company focused on discovering, developing, manufacturing, and selling pharmaceutical products, vaccines, and animal health solutions. The company operates in the healthcare sector, specifically in Brand-Name Pharmaceutical Manufacturing and Animal Health Biotechnology. Merck's business model centers on research and development to deliver innovative health solutions for both human and animal health. Key products include Keytruda and Gardasil, along with antiviral medications, autoimmune prescriptions, cardiovascular prescriptions, diabetes prescriptions, other oncology prescriptions, respiratory prescriptions, and veterinary pharmaceutical and vaccine products. The Animal Health segment provides health management solutions and services for livestock and companion animals.

Merck has a significant global presence, with products reaching various customers worldwide. Key geographic regions for revenue generation include the U.S., Europe, Japan, the Middle East, Africa, China, Latin America, and other parts of Asia Pacific. In 2025, the United States represented the largest share of its total revenue at $36.5 billion, followed by Europe, the Middle East, and Africa at $14.6 billion. Merck also has research and manufacturing facilities in various locations, including West Point, Pennsylvania, Upper Gwynedd, Pennsylvania, South San Francisco, California, and Singapore.

Merck & Co., Inc. maintains a strong brand reputation as a leading research-intensive biopharmaceutical company. It is recognized for its innovative medicines and vaccines, including Keytruda, and is listed on various prestigious rankings such as the Fortune 500, Fortune Global 500, and Forbes Global 2000. The company's purpose is centered on using leading-edge science to save and improve lives globally, and it emphasizes fostering a diverse and inclusive workforce while operating responsibly. No specific events negatively impacting Merck's brand reputation in the past year were found in the provided search results.

Merck & Co., Inc. is predominantly owned by institutional shareholders, who hold approximately 79.70% of the company's stock. Insiders own a smaller portion at 0.22%, and retail investors hold about 20.08%. Vanguard Group Inc. is the largest individual shareholder with 254.32 million shares representing 10.29% of the company. Other significant institutional shareholders are BlackRock, Inc., State Street Corp, Wellington Management Group Llp, Geode Capital Management, Llc, Charles Schwab Investment Management Inc, Morgan Stanley, Fmr Llc, Norges Bank, and Jpmorgan Chase & Co.